Gastrointestinal Therapy Has A New Name
Indicative of its progress towards Phase 3 clinical development, our gastrointestinal product candidate has been granted the name naronapride (ATI-7505).
Learn more
A Growing Clinical Stage Product Pipeline
We are developing a portfolio of novel, oral product candidates aimed at large, chronic markets. We currently have four product candidates in clinical development, three of which are in Phase 3 or are Phase 3 ready.
Learn more
RetroMetabolic Drug Design
We use proprietary technologies to design structurally unique and patentable molecules that retain the efficacy of proven therapies while eliminating specific adverse side effects associated with these therapies.
Learn more
